---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-017439"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2022-06-22T23:59:59+00:00"
generated_at: "2026-06-25T00:11:03.833450+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Oncotelic discloses JV IPO target and OT-101 COVID mortality data at BIO2022

## Summary
- JVCo IPO on track for 2023 with anticipated minimum valuation of $200M, range $1-5B.
- OT-101 combined with immunotherapies including Keytruda (Merck), Tecentriq (Genentech); in various stages.
- OT-101 treatment of high-risk COVID patients reduced mortality from 100% to 50% (p=0.003).
- Company presentation at BIO International Convention available on website.

## SEC filing metadata
- accession: 0001493152-22-017439
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2022-06-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315222017439/0001493152-22-017439-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315222017439/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-017439
- JSON: https://secwatch.observer/filing/0001493152-22-017439.json
- Plain text: https://secwatch.observer/filing/0001493152-22-017439.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.